Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now.
On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock
The firm stated that the company’s Force platform has the potential to improve drug delivery in neuromuscular and CNS diseases by overcoming the related limitations. Pressmaster/ Further, TD Cowen stressed the fact that the company’s late-stage candidates offer the potential to become top-notch therapies. These include z-basivarsen, which targets myotonic dystrophy type 1, and z-rostudirsen, which is used for exon 51 Duchenne muscular dystrophy mutations.
On June 17, Dyne Therapeutics Inc. (NASDAQ:DYN) finalized amendments to its non-dilutive senior secured term loan arrangement with Hercules Capital. As part of the revised arrangement, $50 million had already been funded at the closing of this amendment. In addition to that, Dyne has the option to draw $50 million in term loan tranche, depending on some milestones that need to be achieved.